Kumar A, Singh R, Chauhan A, Sharma D, Sandal R, Chauhan N, Gupta S, Verma B. Outcome of Therapies for Membranous Glomerulonephritis During Three Waves of COVID Pandemic.
Indian J Nephrol 2023;
33:289-291. [PMID:
37781551 PMCID:
PMC10503582 DOI:
10.4103/ijn.ijn_162_22]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2022] [Revised: 07/16/2022] [Accepted: 08/07/2022] [Indexed: 10/03/2023] Open
Abstract
There is lack of clarity on immunosuppressive therapy in glomerular diseases and concomitant corona-virus infection. We retrospectively evaluated 36 patients with primary membranous nephropathy from January 2020 to December 2021 who had received immunosuppression during this period. Diagnosis of COVID-19 was made based on self-reported history of being COVID positive. History of hospitalization and oxygen therapy was noted. Four patients developed COVID-19 in this cohort, and all were infected only once. Two patients had asymptomatic disease and two were hospitalized for severe COVID-19 and had complete recovery. In immunocompromised patients, there is a high risk of infection. This observational study is an attempt to bridge the gap that immunosuppression can precipitate COVID-19 infection.
Collapse